- Open
- 62.50
- High
- 62.50
- Low
- 62.50
- Close
- 62.50
- Change
- -2.50 (-4.00%)
- Volume
- 2
⌘K
| 28 May 2026 | 14:00:00 | Result of AGM |
| 21 May 2026 | 13:00:00 | Grant of options and PDMR dealing |
| 18 May 2026 | 07:00:10 | Upcoming conference attendance |
| 28 Apr 2026 | 16:28:19 | Posting of Annual Report and Notice of AGMm |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor is a biopharmaceutical company with a global reach that aims to improve patient care by developing innovative medicines that enhance existing therapeutic products.
| 28 May 2026 | 14:00:00 | Result of AGM |
| 21 May 2026 | 13:00:00 | Grant of options and PDMR dealing |
| 18 May 2026 | 07:00:10 | Upcoming conference attendance |
| 28 Apr 2026 | 16:28:19 | Posting of Annual Report and Notice of AGMm |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor is a biopharmaceutical company with a global reach that aims to improve patient care by developing innovative medicines that enhance existing therapeutic products.
| 13 Apr 2026 |
| 07:00:06 |
| Final Results |
| 13 Apr 2026 |
| Arecor targets broader AT278 partnership as phase II trial nears |
| 13 Apr 2026 | Arecor Therapeutics CEO on FY25 highlights and progress with AT278 and GLP-1 programmes |
| 26 Mar 2026 | Arecor receives $500k milestone payment from Ligand as royalty deal delivers |
| 13 Apr 2026 |
| 07:00:06 |
| Final Results |
| 13 Apr 2026 |
| Arecor targets broader AT278 partnership as phase II trial nears |
| 13 Apr 2026 | Arecor Therapeutics CEO on FY25 highlights and progress with AT278 and GLP-1 programmes |
| 26 Mar 2026 | Arecor receives $500k milestone payment from Ligand as royalty deal delivers |